Klin Farmakol Farm. 2019;33(3):17-19 | DOI: 10.36290/far.2019.018

Contrast-associated acute kidney injury – up to date 2019

Pavlína Richtrová
I. interní klinika LF UK a FN Plzeň

Contrast-induced nephropathy (CIN) and later used contrast-induced acute kidney injury (CI-AKI) have been mentioned since the 1960s.
It is often considered the 3rd most common cause of kidney injury in hospitalized patients. We define CI-AKI as an increase in serum
creatinine of 25% or 44 μmol/l after 48–72 hours after administration of the contrast agent. Recently, however, our view of this diagnosis
has changed. We have understood various pitfalls and bias of the results of the former studies. In this article we try to summarize the
existing knowledge, describe the missing information and try to offer nephroprotective regime, which seems to be most effective.

Keywords: contrast agent, contrast induced nephropathy, contrast induced acute kidney injury, nephroprotection

Published: October 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Richtrová P. Contrast-associated acute kidney injury – up to date 2019. Klin Farmakol Farm. 2019;33(3):17-19. doi: 10.36290/far.2019.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bartels ED, Brun GC, Gammeltoft A, Gjorup PA. Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med Scand. 1954; 150(4): 297-302. Go to original source... Go to PubMed...
    2. Brodwall EK, Knutsen SB, Myhre JR. Acute renal failure following intravenous pyelography in case of myelomatosis. Acta Med Scand. 1956 Dec 31; 156(4): 263-266. Go to original source... Go to PubMed...
    3. Berlyne N, Berlyne GM. Acute renal failure following intravenous pyelography with hypaque. Acta Med Scand. 1962 Jan; 171: 39-41. Go to original source... Go to PubMed...
    4. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter. 2012; 2(Suppl): 1-138.
    5. Luk L, Steinman J, Newhouse JH. Intravenous Contrast-Induced Nephropathy-The Rise and Fall of a Threatening Idea. Adv Chronic Kidney Dis 2017; 24: 169-175. Go to original source... Go to PubMed...
    6. McDonald RJ, McDonald JS, Newhouse JH, Davenport MS. Controversies in Contrast Material-induced Acute Kidney Injury: Closing in on the Truth? Radiology. 2015 Dec; 277(3): 627-632. Go to original source... Go to PubMed...
    7. Benjamens S, Yakar D, Slart RHJA, Sanders JF, Pol RA. The fear for contrast-induced nephropathy in kidney transplant recipients: time for a paradigm shift? Transpl Int. 2018 May 15. Go to original source... Go to PubMed...
    8. Wilhelm-Leen E, Montez-Rath ME, Chertow G. Estimating the Risk of Radiocontrast-Associated Nephropathy. J Am Soc Nephrol. 2017 Feb; 28(2): 653-659. Go to original source... Go to PubMed...
    9. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol. 2008 Aug; 191(2): 376-382. Go to original source... Go to PubMed...
    10. Caspi O, Habib M, Cohen Y, Kerner A, Roguin A, Abergel E, et al. Acute Kidney Injury After Primary Angioplasty: Is Contrast-Induced Nephropathy the Culprit? J Am Heart Assoc. 2017 Jun 24; 6(6). Go to original source... Go to PubMed...
    11. Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014 May 24; 383(9931): 1814-1823. Go to original source... Go to PubMed...
    12. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 Apr 1; 389(10076): 1312-1322. Go to original source... Go to PubMed...
    13. ACT Invastigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011 Sep 13; 124(11): 1250-1259. Go to original source... Go to PubMed...
    14. Weisbord SD, Gallagher M, Palevsky PM. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018 Feb 15; 378(7): 603-614. Go to original source... Go to PubMed...
    15. Rosenstock JL, Bruno R, Kim JK, et al. Michelis MF. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008; 40(3): 749-755. Go to original source... Go to PubMed...
    16. Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010 Feb 1; 105(3): 288-292. Go to original source... Go to PubMed...
    17. Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrastmaterial: risk stratification by using estimated glomerular filtration rate. Radiology. 2013 Sep; 268(3): 719-728. Go to original source... Go to PubMed...
    18. McDonald RJ, McDonald JS, Carter RE, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology. 2014 Dec; 273(3): 714-725. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.